Antimicrobial Susceptibility Testing Market by Product (Manual, Automated), Type (Antibacterial, Antifungal), Application (Clinical Diagnostics), Method (ETEST, Disk Diffusion, Agar Diffusion, Genotyping), End User & Region - Global Forecasts to 2027
The Antimicrobial Susceptibility Testing market is projected to reach USD 4.7 billion by 2027 from USD 3.6 billion in 2022, at a CAGR of 5.5% during the forecast period. The significant growth of the antimicrobial susceptibility testing market is largely due to the overuse and misuse of antibiotics, which resuresistance microbial resistances (AMR), and the increased use of antimicrobial susceptibility testing by biopharmaceutical, biotechnological, and pharmaceutical companies.
“The automated laboratory instruments to hold the largest share of the market in 2022”
Automated laboratory instruments holds the largest market share in 2022. Automated identification and susceptibility systems are more expensive than manual conventional ones but offer the advantage of quicker findings. Although automated methods are more efficient and of higher quality, some bacteria and antimicrobial agents have specific technological limitations.
“The Antibacterial infections is holding the largest share of the market in 2022”
Based on type, the antimicrobial susceptibility testing market is classified into antibacterial susceptibility testing, antifungal susceptibility testing, antiparasitic susceptibility testing and other susceptibility testing. The large share of this segment is attributed to the presence of regulatory guidelines to streamline the process of antibacterial susceptibility testing, technological advancements in this segment, and the rising burden of antibacterial resistance in developing and developed countries.
“The market in North America region is expected to witness the highest growth during the forecast period.”
North America accounted for the largest market share—35.4%—in 2022. The increasing R&D to develop novel automated AST systems, rising prevalence of infectious diseases, growing safety concerns, and technological advancements in antimicrobial susceptibility testing products are the key factors supporting market growth in North America
While the APAC is expected to witness significant growth in the coming years. The antimicrobial susceptibility testing market in the APAC region is expected to register a CAGR of 6.7% during the forecast period, primarily due to the growing number of hospitals in Asian countries and favorable government initiatives.
A breakdown of the primary participants referred to for this report is provided below:
Research Coverage
This report studies the Antimicrobial susceptibility testing market based on product, design, end user and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established and entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.
This report provides insights on the following pointers:
“The automated laboratory instruments to hold the largest share of the market in 2022”
Automated laboratory instruments holds the largest market share in 2022. Automated identification and susceptibility systems are more expensive than manual conventional ones but offer the advantage of quicker findings. Although automated methods are more efficient and of higher quality, some bacteria and antimicrobial agents have specific technological limitations.
“The Antibacterial infections is holding the largest share of the market in 2022”
Based on type, the antimicrobial susceptibility testing market is classified into antibacterial susceptibility testing, antifungal susceptibility testing, antiparasitic susceptibility testing and other susceptibility testing. The large share of this segment is attributed to the presence of regulatory guidelines to streamline the process of antibacterial susceptibility testing, technological advancements in this segment, and the rising burden of antibacterial resistance in developing and developed countries.
“The market in North America region is expected to witness the highest growth during the forecast period.”
North America accounted for the largest market share—35.4%—in 2022. The increasing R&D to develop novel automated AST systems, rising prevalence of infectious diseases, growing safety concerns, and technological advancements in antimicrobial susceptibility testing products are the key factors supporting market growth in North America
While the APAC is expected to witness significant growth in the coming years. The antimicrobial susceptibility testing market in the APAC region is expected to register a CAGR of 6.7% during the forecast period, primarily due to the growing number of hospitals in Asian countries and favorable government initiatives.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3– 30%
- By Designation: C-level–27%, Director-level–18%, and Others–55%
- By Region: North America–35.3%, Europe–20%, Asia Pacific–15%, Latin America–10%, and the Middle East & Africa–5%
Research Coverage
This report studies the Antimicrobial susceptibility testing market based on product, design, end user and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established and entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.
This report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the microcatheter market.
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the microcatheter market.
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the microcatheter market.
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from primary experts
2.1.2.3 Breakdown of primaries
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 5 TOP-DOWN APPROACH
FIGURE 6 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ESTIMATION
2.5 RESEARCH ASSUMPTIONS
2.6 LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 1 LIMITATIONS AND ASSOCIATED RISKS
2.8 IMPACT OF RECESSION ON ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
3 EXECUTIVE SUMMARY
FIGURE 8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 9 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY TYPE, 2022 VS. 2027
FIGURE 10 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 11 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2022 VS. 2027 (USD MILLION)
FIGURE 12 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY END USER, 2022 VS. 2027
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
4 PREMIUM INSIGHTS
4.1 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET OVERVIEW
FIGURE 14 TECHNOLOGICAL ADVANCEMENTS AND RISING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
4.2 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 15 SUSCEPTIBILITY TESTING DISKS SEGMENT TO DOMINATE MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET
4.3 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY AND TYPE
FIGURE 16 ANTIBACTERIAL SUSCEPTIBILITY TESTING SEGMENT TO DOMINATE NORTH AMERICAN MARKET
4.4 GEOGRAPHIC SNAPSHOT: KEY GROWTH OPPORTUNITIES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
FIGURE 17 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of infectious diseases coupled with epidemic and pandemic events
5.2.1.2 Increasing funding, research grants, and public-private investments
5.2.1.3 Technological advancements
5.2.1.4 Growing government initiatives to detect and control antimicrobial-resistant species
5.2.1.5 Emergence of multidrug resistance due to drug abuse
5.2.2 RESTRAINTS
5.2.2.1 High cost of automated ID/AST systems
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging markets
5.2.4 CHALLENGES
5.2.4.1 Complex regulatory frameworks
5.3 PORTER’S FIVE FORCES ANALYSIS
5.3.1 OVERVIEW
TABLE 2 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.2 THREAT OF NEW ENTRANTS
5.3.3 THREAT OF SUBSTITUTES
5.3.4 BARGAINING POWER OF SUPPLIERS
5.3.5 BARGAINING POWER OF BUYERS
5.3.6 INTENSITY OF COMPETITIVE RIVALRY
5.4 REGULATORY ANALYSIS
5.4.1 NORTH AMERICA
5.4.1.1 US
TABLE 3 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 4 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.4.1.2 Canada
TABLE 5 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.4.2 EUROPE
5.4.3 ASIA PACIFIC
5.4.3.1 Japan
TABLE 6 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICALS AND MEDICAL DEVICES AGENCY
5.4.3.2 China
TABLE 7 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.4.3.3 India
5.5 ECOSYSTEM ANALYSIS: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
FIGURE 19 ECOSYSTEM COVERAGE
5.6 VALUE CHAIN ANALYSIS
5.6.1 RESEARCH & DEVELOPMENT
5.6.2 MANUFACTURING AND ASSEMBLY
5.6.3 DISTRIBUTION, MARKETING AND SALES, AND POST-SALES SERVICES
FIGURE 20 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: VALUE CHAIN ANALYSIS
5.7 SUPPLY CHAIN ANALYSIS
5.7.1 PROMINENT COMPANIES
5.7.2 SMALL AND MEDIUM-SIZED ENTERPRISES
FIGURE 21 SUPPLY CHAIN ANALYSIS
5.8 KEY CONFERENCES AND EVENTS IN 2023–2024
TABLE 8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DETAILED LIST OF MAJOR CONFERENCES AND EVENTS
5.9 KEY STAKEHOLDERS AND BUYING CRITERIA
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS
TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS
5.9.2 BUYING CRITERIA
FIGURE 23 KEY BUYING CRITERIA FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS
TABLE 10 KEY BUYING CRITERIA FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS
5.10 PATENT ANALYSIS
FIGURE 24 TOP 10 PATENT APPLICANTS
FIGURE 25 TOP 10 PATENT OWNERS
6 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 11 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
6.2 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS
TABLE 12 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 13 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.1 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE
TABLE 14 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2.2 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY APPLICATION
TABLE 15 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
6.2.3 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY METHOD
TABLE 16 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY METHOD, 2020–2027 (USD MILLION)
6.2.4 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY END USER
TABLE 17 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION)
6.2.5 SUSCEPTIBILITY TESTING DISKS
6.2.5.1 Significant adoption of disk diffusion tests in emerging countries to support segment growth
TABLE 18 SUSCEPTIBILITY TESTING DISKS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.5.2 Susceptibility testing disks market, by type
TABLE 19 SUSCEPTIBILITY TESTING DISKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2.5.3 Susceptibility testing disks market, by application
TABLE 20 SUSCEPTIBILITY TESTING DISKS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
6.2.5.4 Susceptibility testing disks market, by method
TABLE 21 SUSCEPTIBILITY TESTING DISKS MARKET, BY METHOD, 2020–2027 (USD MILLION)
6.2.5.5 Susceptibility testing disks market, by end user
TABLE 22 SUSCEPTIBILITY TESTING DISKS MARKET, BY END USER, 2020–2027 (USD MILLION)
6.2.6 MIC STRIPS
6.2.6.1 Growing adoption of broad-spectrum MIC strips to support market growth
TABLE 23 MIC STRIPS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.6.2 MIC strips market, by type
TABLE 24 MIC STRIPS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2.6.3 MIC strips market, by application
TABLE 25 MIC STRIPS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
6.2.6.4 MIC strips market, by method
TABLE 26 MIC STRIPS MARKET, BY METHOD, 2020–2027 (USD MILLION)
6.2.6.5 MIC strips market, by end user
TABLE 27 MIC STRIPS MARKET, BY END USER, 2020–2027 (USD MILLION)
6.2.7 SUSCEPTIBILITY TESTING PLATES
6.2.7.1 Increasing adoption of automated/rapid AST systems hampering growth
TABLE 28 SUSCEPTIBILITY TESTING PLATES MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.7.2 Susceptibility testing plates market, by type
TABLE 29 SUSCEPTIBILITY TESTING PLATES MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2.7.3 Susceptibility testing plates market, by application
TABLE 30 SUSCEPTIBILITY TESTING PLATES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
6.2.7.4 Susceptibility testing plates market, by method
TABLE 31 SUSCEPTIBILITY TESTING PLATES MARKET, BY METHOD, 2020–2027 (USD MILLION)
6.2.7.5 Susceptibility testing plates market, by end user
TABLE 32 SUSCEPTIBILITY TESTING PLATES MARKET, BY END USER, 2020–2027 (USD MILLION)
6.3 AUTOMATED LABORATORY INSTRUMENTS
6.3.1 ONGOING TREND OF LABORATORY AUTOMATION AMONG CLINICAL LABORATORIES TO FUEL GROWTH
TABLE 33 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.2 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY TYPE
TABLE 34 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.3.3 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY APPLICATION
TABLE 35 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
6.3.4 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY METHOD
TABLE 36 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY METHOD, 2020–2027 (USD MILLION)
6.3.5 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY END USER
TABLE 37 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
6.4 CULTURE AND GROWTH MEDIA
6.4.1 HIGH UTILIZATION OF DISK DIFFUSION AND BROTH DILUTION METHODS TO DRIVE GROWTH
TABLE 38 CULTURE AND GROWTH MEDIA MARKET, BY REGION, 2020–2027 (USD MILLION)
6.4.2 CULTURE AND GROWTH MEDIA MARKET, BY TYPE
TABLE 39 CULTURE AND GROWTH MEDIA MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.4.3 CULTURE AND GROWTH MEDIA MARKET, BY APPLICATION
TABLE 40 CULTURE AND GROWTH MEDIA MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
6.4.4 CULTURE AND GROWTH MEDIA MARKET, BY METHOD
TABLE 41 CULTURE AND GROWTH MEDIA MARKET, BY METHOD, 2020–2027 (USD MILLION)
6.4.5 CULTURE AND GROWTH MEDIA MARKET, BY END USER
TABLE 42 CULTURE AND GROWTH MEDIA MARKET, BY END USER, 2020–2027 (USD MILLION)
6.5 CONSUMABLES
6.5.1 INCREASING NUMBER OF SUSCEPTIBILITY TESTS PERFORMED AT HOSPITALS TO SUPPORT GROWTH
TABLE 43 CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
6.5.2 CONSUMABLES MARKET, BY TYPE
TABLE 44 CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.5.3 CONSUMABLES MARKET, BY APPLICATION
TABLE 45 CONSUMABLES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
6.5.4 CONSUMABLES MARKET, BY METHOD
TABLE 46 CONSUMABLES MARKET, BY METHOD, 2020–2027 (USD MILLION)
6.5.5 CONSUMABLES MARKET, BY END USER
TABLE 47 CONSUMABLES MARKET, BY END USER, 2020–2027 (USD MILLION)
7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE
7.1 INTRODUCTION
TABLE 48 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
7.2 ANTIBACTERIAL SUSCEPTIBILITY TESTING
7.2.1 EMERGENCE OF MULTIDRUG-RESISTANCE TO INCREASE ADOPTION OF ANTIBACTERIAL SUSCEPTIBILITY TESTING PRODUCTS
TABLE 49 ANTIBACTERIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
7.3 ANTIFUNGAL SUSCEPTIBILITY TESTING
7.3.1 INCREASING INFECTIONS OF CANDIDA AND ASPERGILLUS SPECIES TO DRIVE GROWTH
TABLE 50 NUMBER OF HOSPITALIZATIONS AND DIRECT MEDICAL COSTS ASSOCIATED WITH FUNGAL DISEASES IN US FOR FY 2019
TABLE 51 ANTIFUNGAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
7.4 ANTIPARASITIC SUSCEPTIBILITY TESTING
7.4.1 RISING INITIATIVES TO CREATE AWARENESS ABOUT PARASITIC INFECTIONS TO DRIVE GROWTH
TABLE 52 ANTIPARASITIC SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
7.5 OTHER SUSCEPTIBILITY TESTING
TABLE 53 OTHER SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 54 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.2 CLINICAL DIAGNOSTICS
8.2.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASING NUMBER OF SUSCEPTIBILITY TESTS PERFORMED TO DRIVE GROWTH
TABLE 55 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
8.3 DRUG DISCOVERY AND DEVELOPMENT
8.3.1 RISING ADOPTION OF RAPID AST SOLUTIONS BY BIOPHARMACEUTICAL COMPANIES TO DRIVE SEGMENT GROWTH
TABLE 56 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION)
8.4 EPIDEMIOLOGY
8.4.1 OUTBREAK OF PANDEMICS AND EPIDEMICS TO DRIVE DEMAND FOR AST PRODUCTS
TABLE 57 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR EPIDEMIOLOGY, BY REGION, 2020–2027 (USD MILLION)
8.5 OTHER APPLICATIONS
TABLE 58 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD
9.1 INTRODUCTION
TABLE 59 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION)
9.2 AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING
9.2.1 TECHNOLOGICAL ADVANCEMENTS AND FAVORABLE PRODUCT PIPELINE TO DRIVE GROWTH
TABLE 60 AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
9.3 DISK DIFFUSION
9.3.1 RISING INCIDENCE OF URINARY TRACT INFECTIONS TO DRIVE GROWTH
TABLE 61 DISK DIFFUSION-BASED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
9.4 AGAR DILUTION
9.4.1 AGAR DILUTION HELPS EXPLORE DRUG COMBINATIONS FOR COMBINED ANTIBIOTIC THERAPY
TABLE 62 AGAR DILUTION-BASED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
9.5 ETEST
9.5.1 UNCERTAINTIES IN RESULT INTERPRETATION AFFECTING MARKET GROWTH
TABLE 63 ETEST-BASED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
9.6 GENOTYPIC METHODS
9.6.1 ONGOING CLINICAL TRIALS AND UPCOMING PRODUCT LAUNCHES SUPPORT GROWTH
TABLE 64 GENOTYPIC METHODS-BASED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
10 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER
10.1 INTRODUCTION
TABLE 65 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2 HOSPITALS AND DIAGNOSTIC CENTERS
10.2.1 HIGH PREVALENCE OF INFECTIOUS DISEASES AND RISING ADOPTION OF RAPID AST SOLUTIONS TO DRIVE GROWTH
TABLE 66 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION)
10.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
10.3.1 INCREASING NUMBER OF BIOPHARMACEUTICAL COMPANIES TO SUPPORT SEGMENT GROWTH
TABLE 67 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
10.4 RESEARCH AND ACADEMIC INSTITUTES
10.4.1 GROWING RESEARCH GRANTS AND FUNDING TO ACCELERATE MARKET GROWTH
TABLE 68 FUNDING BY DEPARTMENT OF HEALTH AND SOCIAL CARE (UK) FOR ANTIMICROBIAL RESISTANCE STUDIES, 2020
TABLE 69 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
10.5 CONTRACT RESEARCH ORGANIZATIONS
10.5.1 CLINICAL TRIAL GLOBALIZATION AND GROWING NUMBER OF CROS IN EMERGING ECONOMIES TO DRIVE GROWTH
TABLE 70 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION)
11 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION
11.1 INTRODUCTION
TABLE 71 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 26 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SNAPSHOT
TABLE 72 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 73 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 74 NORTH AMERICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 77 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 78 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.1 US
11.2.1.1 US to dominate North American market during forecast period
TABLE 79 US: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 80 US: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Favorable government initiatives to drive growth during forecast period
TABLE 81 CANADA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 82 CANADA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.3 EUROPE
TABLE 83 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 84 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 85 EUROPE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 86 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 87 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 88 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 89 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Germany to dominate European market during forecast period
TABLE 90 GERMANY: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 91 GERMANY: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.3.2 FRANCE
11.3.2.1 Supportive government policies and easy access to healthcare services to fuel growth
TABLE 92 FRANCE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 93 FRANCE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.3.3 UK
11.3.3.1 Significant prevalence of infectious diseases coupled with increasing awareness of AST products to drive market growth
TABLE 94 UK: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 95 UK: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Increasing R&D investments by pharmaceutical companies to propel demand for AST products
TABLE 96 ITALY: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 97 ITALY: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Rising geriatric population to drive market growth
TABLE 98 SPAIN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 99 SPAIN: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 100 REST OF EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 101 REST OF EUROPE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 27 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SNAPSHOT
TABLE 102 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 103 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 104 ASIA PACIFIC: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 105 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 106 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 107 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 108 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.1 JAPAN
11.4.1.1 Growing geriatric population to drive market
TABLE 109 JAPAN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 110 JAPAN: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Favorable government regulations and heavy burden of infectious diseases to drive market growth
TABLE 111 INCIDENCE OF INFECTIOUS DISEASES IN CHINA, 2020
TABLE 112 CHINA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 113 CHINA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Growing initiatives for clinical diagnosis by government and major players to drive market growth
TABLE 114 INDIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 115 INDIA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.4.4 AUSTRALIA
11.4.4.1 Increasing government funding for research activities to drive market growth
TABLE 116 AUSTRALIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 117 AUSTRALIA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.4.5 SOUTH KOREA
11.4.5.1 Requirement of rapid AMR detection to drive growth
TABLE 118 SOUTH KOREA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 119 SOUTH KOREA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.4.6 REST OF ASIA PACIFIC
TABLE 120 REST OF ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 121 REST OF ASIA PACIFIC: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.5 LATIN AMERICA
TABLE 122 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 123 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 124 LATIN AMERICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 125 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 126 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 127 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 128 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 Established presence of major AST product manufacturers to drive growth
TABLE 129 BRAZIL: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 130 BRAZIL: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.5.2 MEXICO
11.5.2.1 Growing economic development to drive market growth
TABLE 131 MEXICO: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 132 MEXICO: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.5.3 REST OF LATIN AMERICA
TABLE 133 REST OF LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 134 REST OF LATIN AMERICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 GROWING INCIDENCE OF INFECTIOUS DISEASES AND LARGE PATIENT POOL TO DRIVE MARKET GROWTH
TABLE 135 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 136 MIDDLE EAST & AFRICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 137 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 138 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 139 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 140 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 STRATEGIES OF KEY PLAYERS/RIGHT TO WIN
TABLE 141 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 28 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
12.4 MARKET SHARE ANALYSIS (2021)
FIGURE 29 BIOM?RIEUX SA HELD LEADING POSITION IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET IN 2021
12.5 COMPANY EVALUATION MATRIX FOR 25 MAJOR PLAYERS (2021)
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 30 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2021
12.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2021)
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 31 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: COMPANY EVALUATION MATRIX FOR SMES/START-UPS, 2021
12.7 COMPETITIVE BENCHMARKING
TABLE 142 PRODUCT FOOTPRINT ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
TABLE 143 APPLICATION FOOTPRINT ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
TABLE 144 REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
12.8 COMPETITIVE SCENARIO
12.8.1 PRODUCT LAUNCHES
TABLE 145 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: PRODUCT LAUNCHES, JANUARY 2020–JANUARY 2023
12.8.2 DEALS
TABLE 146 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DEALS, JANUARY 2020–JANUARY 2023
13 COMPANY PROFILES
(Business overview, Products offered, Recent Developments, MNM view)*
13.1 KEY PLAYERS
13.1.1 BIOM?RIEUX SA
TABLE 147 COMPANY OVERVIEW: BIOM?RIEUX SA
FIGURE 32 BIOM?RIEUX SA: COMPANY SNAPSHOT
13.1.2 BECTON, DICKINSON AND COMPANY
TABLE 148 COMPANY OVERVIEW: BECTON, DICKINSON AND COMPANY
FIGURE 33 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
13.1.3 THERMO FISHER SCIENTIFIC
TABLE 149 COMPANY OVERVIEW: THERMO FISHER SCIENTIFIC
FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
13.1.4 DANAHER CORPORATION
TABLE 150 COMPANY OVERVIEW: DANAHER CORPORATION
FIGURE 35 DANAHER CORPORATION: COMPANY SNAPSHOT
13.1.5 BIO-RAD LABORATORIES, INC.
TABLE 151 COMPANY OVERVIEW: BIO-RAD LABORATORIES, INC.
FIGURE 36 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
13.1.6 BRUKER
TABLE 152 COMPANY OVERVIEW: BRUKER
FIGURE 37 BRUKER: COMPANY SNAPSHOT
13.1.7 ROCHE DIAGNOSTICS
TABLE 153 COMPANY OVERVIEW: ROCHE DIAGNOSTICS
FIGURE 38 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
13.1.8 MERCK KGAA
TABLE 154 COMPANY OVERVIEW: MERCK KGAA
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT
13.1.9 ACCELERATE DIAGNOSTICS, INC.
TABLE 155 COMPANY OVERVIEW: ACCELERATE DIAGNOSTICS, INC.
FIGURE 40 ACCELERATE DIAGNOSTICS, INC.: COMPANY SNAPSHOT
13.1.10 HIMEDIA LABORATORIES
TABLE 156 COMPANY OVERVIEW: HIMEDIA LABORATORIES
13.1.11 LIOFILCHEM S.R.L.
TABLE 157 COMPANY OVERVIEW: LIOFILCHEM S.R.L.
13.1.12 ALIFAX S.R.L.
TABLE 158 COMPANY OVERVIEW: ALIFAX S.R.L.
13.1.13 CREATIVE DIAGNOSTICS
TABLE 159 COMPANY OVERVIEW: CREATIVE DIAGNOSTICS
13.1.14 SYNBIOSIS
TABLE 160 COMPANY OVERVIEW: SYNBIOSIS
13.1.15 BIOANALYSE
TABLE 161 COMPANY OVERVIEW: BIOANALYSE
13.2 OTHER COMPANIES
13.2.1 ZHUHAI DL BIOTECH CO., LTD.
13.2.2 ELITECH GROUP
13.2.3 MAST GROUP LTD.
13.2.4 CONDALAB
13.2.5 GENEFLUIDICS, INC.
13.2.6 BIOTRON LTD.
13.2.7 INVIVOGEN
13.2.8 MP BIOMEDICALS
13.2.9 QUANTAMATRIX INC.
13.2.10 PML MICROBIOLOGICALS
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 REGIONS COVERED
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Insights from primary experts
2.1.2.3 Breakdown of primaries
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 5 TOP-DOWN APPROACH
FIGURE 6 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ESTIMATION
2.5 RESEARCH ASSUMPTIONS
2.6 LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 1 LIMITATIONS AND ASSOCIATED RISKS
2.8 IMPACT OF RECESSION ON ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
3 EXECUTIVE SUMMARY
FIGURE 8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 9 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY TYPE, 2022 VS. 2027
FIGURE 10 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 11 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2022 VS. 2027 (USD MILLION)
FIGURE 12 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY END USER, 2022 VS. 2027
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
4 PREMIUM INSIGHTS
4.1 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET OVERVIEW
FIGURE 14 TECHNOLOGICAL ADVANCEMENTS AND RISING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
4.2 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 15 SUSCEPTIBILITY TESTING DISKS SEGMENT TO DOMINATE MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET
4.3 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY AND TYPE
FIGURE 16 ANTIBACTERIAL SUSCEPTIBILITY TESTING SEGMENT TO DOMINATE NORTH AMERICAN MARKET
4.4 GEOGRAPHIC SNAPSHOT: KEY GROWTH OPPORTUNITIES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
FIGURE 17 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of infectious diseases coupled with epidemic and pandemic events
5.2.1.2 Increasing funding, research grants, and public-private investments
5.2.1.3 Technological advancements
5.2.1.4 Growing government initiatives to detect and control antimicrobial-resistant species
5.2.1.5 Emergence of multidrug resistance due to drug abuse
5.2.2 RESTRAINTS
5.2.2.1 High cost of automated ID/AST systems
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging markets
5.2.4 CHALLENGES
5.2.4.1 Complex regulatory frameworks
5.3 PORTER’S FIVE FORCES ANALYSIS
5.3.1 OVERVIEW
TABLE 2 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS
5.3.2 THREAT OF NEW ENTRANTS
5.3.3 THREAT OF SUBSTITUTES
5.3.4 BARGAINING POWER OF SUPPLIERS
5.3.5 BARGAINING POWER OF BUYERS
5.3.6 INTENSITY OF COMPETITIVE RIVALRY
5.4 REGULATORY ANALYSIS
5.4.1 NORTH AMERICA
5.4.1.1 US
TABLE 3 US FDA: MEDICAL DEVICE CLASSIFICATION
TABLE 4 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.4.1.2 Canada
TABLE 5 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
5.4.2 EUROPE
5.4.3 ASIA PACIFIC
5.4.3.1 Japan
TABLE 6 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICALS AND MEDICAL DEVICES AGENCY
5.4.3.2 China
TABLE 7 CHINA: CLASSIFICATION OF MEDICAL DEVICES
5.4.3.3 India
5.5 ECOSYSTEM ANALYSIS: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
FIGURE 19 ECOSYSTEM COVERAGE
5.6 VALUE CHAIN ANALYSIS
5.6.1 RESEARCH & DEVELOPMENT
5.6.2 MANUFACTURING AND ASSEMBLY
5.6.3 DISTRIBUTION, MARKETING AND SALES, AND POST-SALES SERVICES
FIGURE 20 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: VALUE CHAIN ANALYSIS
5.7 SUPPLY CHAIN ANALYSIS
5.7.1 PROMINENT COMPANIES
5.7.2 SMALL AND MEDIUM-SIZED ENTERPRISES
FIGURE 21 SUPPLY CHAIN ANALYSIS
5.8 KEY CONFERENCES AND EVENTS IN 2023–2024
TABLE 8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DETAILED LIST OF MAJOR CONFERENCES AND EVENTS
5.9 KEY STAKEHOLDERS AND BUYING CRITERIA
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS
TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS
5.9.2 BUYING CRITERIA
FIGURE 23 KEY BUYING CRITERIA FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS
TABLE 10 KEY BUYING CRITERIA FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS
5.10 PATENT ANALYSIS
FIGURE 24 TOP 10 PATENT APPLICANTS
FIGURE 25 TOP 10 PATENT OWNERS
6 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 11 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
6.2 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS
TABLE 12 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 13 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.1 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE
TABLE 14 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2.2 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY APPLICATION
TABLE 15 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
6.2.3 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY METHOD
TABLE 16 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY METHOD, 2020–2027 (USD MILLION)
6.2.4 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY END USER
TABLE 17 MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY END USER, 2020–2027 (USD MILLION)
6.2.5 SUSCEPTIBILITY TESTING DISKS
6.2.5.1 Significant adoption of disk diffusion tests in emerging countries to support segment growth
TABLE 18 SUSCEPTIBILITY TESTING DISKS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.5.2 Susceptibility testing disks market, by type
TABLE 19 SUSCEPTIBILITY TESTING DISKS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2.5.3 Susceptibility testing disks market, by application
TABLE 20 SUSCEPTIBILITY TESTING DISKS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
6.2.5.4 Susceptibility testing disks market, by method
TABLE 21 SUSCEPTIBILITY TESTING DISKS MARKET, BY METHOD, 2020–2027 (USD MILLION)
6.2.5.5 Susceptibility testing disks market, by end user
TABLE 22 SUSCEPTIBILITY TESTING DISKS MARKET, BY END USER, 2020–2027 (USD MILLION)
6.2.6 MIC STRIPS
6.2.6.1 Growing adoption of broad-spectrum MIC strips to support market growth
TABLE 23 MIC STRIPS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.6.2 MIC strips market, by type
TABLE 24 MIC STRIPS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2.6.3 MIC strips market, by application
TABLE 25 MIC STRIPS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
6.2.6.4 MIC strips market, by method
TABLE 26 MIC STRIPS MARKET, BY METHOD, 2020–2027 (USD MILLION)
6.2.6.5 MIC strips market, by end user
TABLE 27 MIC STRIPS MARKET, BY END USER, 2020–2027 (USD MILLION)
6.2.7 SUSCEPTIBILITY TESTING PLATES
6.2.7.1 Increasing adoption of automated/rapid AST systems hampering growth
TABLE 28 SUSCEPTIBILITY TESTING PLATES MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.7.2 Susceptibility testing plates market, by type
TABLE 29 SUSCEPTIBILITY TESTING PLATES MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2.7.3 Susceptibility testing plates market, by application
TABLE 30 SUSCEPTIBILITY TESTING PLATES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
6.2.7.4 Susceptibility testing plates market, by method
TABLE 31 SUSCEPTIBILITY TESTING PLATES MARKET, BY METHOD, 2020–2027 (USD MILLION)
6.2.7.5 Susceptibility testing plates market, by end user
TABLE 32 SUSCEPTIBILITY TESTING PLATES MARKET, BY END USER, 2020–2027 (USD MILLION)
6.3 AUTOMATED LABORATORY INSTRUMENTS
6.3.1 ONGOING TREND OF LABORATORY AUTOMATION AMONG CLINICAL LABORATORIES TO FUEL GROWTH
TABLE 33 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.2 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY TYPE
TABLE 34 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.3.3 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY APPLICATION
TABLE 35 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
6.3.4 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY METHOD
TABLE 36 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY METHOD, 2020–2027 (USD MILLION)
6.3.5 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY END USER
TABLE 37 AUTOMATED LABORATORY INSTRUMENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
6.4 CULTURE AND GROWTH MEDIA
6.4.1 HIGH UTILIZATION OF DISK DIFFUSION AND BROTH DILUTION METHODS TO DRIVE GROWTH
TABLE 38 CULTURE AND GROWTH MEDIA MARKET, BY REGION, 2020–2027 (USD MILLION)
6.4.2 CULTURE AND GROWTH MEDIA MARKET, BY TYPE
TABLE 39 CULTURE AND GROWTH MEDIA MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.4.3 CULTURE AND GROWTH MEDIA MARKET, BY APPLICATION
TABLE 40 CULTURE AND GROWTH MEDIA MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
6.4.4 CULTURE AND GROWTH MEDIA MARKET, BY METHOD
TABLE 41 CULTURE AND GROWTH MEDIA MARKET, BY METHOD, 2020–2027 (USD MILLION)
6.4.5 CULTURE AND GROWTH MEDIA MARKET, BY END USER
TABLE 42 CULTURE AND GROWTH MEDIA MARKET, BY END USER, 2020–2027 (USD MILLION)
6.5 CONSUMABLES
6.5.1 INCREASING NUMBER OF SUSCEPTIBILITY TESTS PERFORMED AT HOSPITALS TO SUPPORT GROWTH
TABLE 43 CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
6.5.2 CONSUMABLES MARKET, BY TYPE
TABLE 44 CONSUMABLES MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.5.3 CONSUMABLES MARKET, BY APPLICATION
TABLE 45 CONSUMABLES MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
6.5.4 CONSUMABLES MARKET, BY METHOD
TABLE 46 CONSUMABLES MARKET, BY METHOD, 2020–2027 (USD MILLION)
6.5.5 CONSUMABLES MARKET, BY END USER
TABLE 47 CONSUMABLES MARKET, BY END USER, 2020–2027 (USD MILLION)
7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE
7.1 INTRODUCTION
TABLE 48 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
7.2 ANTIBACTERIAL SUSCEPTIBILITY TESTING
7.2.1 EMERGENCE OF MULTIDRUG-RESISTANCE TO INCREASE ADOPTION OF ANTIBACTERIAL SUSCEPTIBILITY TESTING PRODUCTS
TABLE 49 ANTIBACTERIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
7.3 ANTIFUNGAL SUSCEPTIBILITY TESTING
7.3.1 INCREASING INFECTIONS OF CANDIDA AND ASPERGILLUS SPECIES TO DRIVE GROWTH
TABLE 50 NUMBER OF HOSPITALIZATIONS AND DIRECT MEDICAL COSTS ASSOCIATED WITH FUNGAL DISEASES IN US FOR FY 2019
TABLE 51 ANTIFUNGAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
7.4 ANTIPARASITIC SUSCEPTIBILITY TESTING
7.4.1 RISING INITIATIVES TO CREATE AWARENESS ABOUT PARASITIC INFECTIONS TO DRIVE GROWTH
TABLE 52 ANTIPARASITIC SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
7.5 OTHER SUSCEPTIBILITY TESTING
TABLE 53 OTHER SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
8 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION
8.1 INTRODUCTION
TABLE 54 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.2 CLINICAL DIAGNOSTICS
8.2.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASING NUMBER OF SUSCEPTIBILITY TESTS PERFORMED TO DRIVE GROWTH
TABLE 55 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
8.3 DRUG DISCOVERY AND DEVELOPMENT
8.3.1 RISING ADOPTION OF RAPID AST SOLUTIONS BY BIOPHARMACEUTICAL COMPANIES TO DRIVE SEGMENT GROWTH
TABLE 56 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR DRUG DISCOVERY AND DEVELOPMENT, BY REGION, 2020–2027 (USD MILLION)
8.4 EPIDEMIOLOGY
8.4.1 OUTBREAK OF PANDEMICS AND EPIDEMICS TO DRIVE DEMAND FOR AST PRODUCTS
TABLE 57 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR EPIDEMIOLOGY, BY REGION, 2020–2027 (USD MILLION)
8.5 OTHER APPLICATIONS
TABLE 58 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD
9.1 INTRODUCTION
TABLE 59 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION)
9.2 AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING
9.2.1 TECHNOLOGICAL ADVANCEMENTS AND FAVORABLE PRODUCT PIPELINE TO DRIVE GROWTH
TABLE 60 AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
9.3 DISK DIFFUSION
9.3.1 RISING INCIDENCE OF URINARY TRACT INFECTIONS TO DRIVE GROWTH
TABLE 61 DISK DIFFUSION-BASED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
9.4 AGAR DILUTION
9.4.1 AGAR DILUTION HELPS EXPLORE DRUG COMBINATIONS FOR COMBINED ANTIBIOTIC THERAPY
TABLE 62 AGAR DILUTION-BASED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
9.5 ETEST
9.5.1 UNCERTAINTIES IN RESULT INTERPRETATION AFFECTING MARKET GROWTH
TABLE 63 ETEST-BASED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
9.6 GENOTYPIC METHODS
9.6.1 ONGOING CLINICAL TRIALS AND UPCOMING PRODUCT LAUNCHES SUPPORT GROWTH
TABLE 64 GENOTYPIC METHODS-BASED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
10 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER
10.1 INTRODUCTION
TABLE 65 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2 HOSPITALS AND DIAGNOSTIC CENTERS
10.2.1 HIGH PREVALENCE OF INFECTIOUS DISEASES AND RISING ADOPTION OF RAPID AST SOLUTIONS TO DRIVE GROWTH
TABLE 66 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION)
10.3 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
10.3.1 INCREASING NUMBER OF BIOPHARMACEUTICAL COMPANIES TO SUPPORT SEGMENT GROWTH
TABLE 67 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
10.4 RESEARCH AND ACADEMIC INSTITUTES
10.4.1 GROWING RESEARCH GRANTS AND FUNDING TO ACCELERATE MARKET GROWTH
TABLE 68 FUNDING BY DEPARTMENT OF HEALTH AND SOCIAL CARE (UK) FOR ANTIMICROBIAL RESISTANCE STUDIES, 2020
TABLE 69 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
10.5 CONTRACT RESEARCH ORGANIZATIONS
10.5.1 CLINICAL TRIAL GLOBALIZATION AND GROWING NUMBER OF CROS IN EMERGING ECONOMIES TO DRIVE GROWTH
TABLE 70 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION)
11 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION
11.1 INTRODUCTION
TABLE 71 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 26 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SNAPSHOT
TABLE 72 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 73 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 74 NORTH AMERICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 77 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 78 NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.1 US
11.2.1.1 US to dominate North American market during forecast period
TABLE 79 US: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 80 US: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Favorable government initiatives to drive growth during forecast period
TABLE 81 CANADA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 82 CANADA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.3 EUROPE
TABLE 83 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 84 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 85 EUROPE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 86 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 87 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 88 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 89 EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Germany to dominate European market during forecast period
TABLE 90 GERMANY: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 91 GERMANY: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.3.2 FRANCE
11.3.2.1 Supportive government policies and easy access to healthcare services to fuel growth
TABLE 92 FRANCE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 93 FRANCE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.3.3 UK
11.3.3.1 Significant prevalence of infectious diseases coupled with increasing awareness of AST products to drive market growth
TABLE 94 UK: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 95 UK: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Increasing R&D investments by pharmaceutical companies to propel demand for AST products
TABLE 96 ITALY: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 97 ITALY: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Rising geriatric population to drive market growth
TABLE 98 SPAIN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 99 SPAIN: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 100 REST OF EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 101 REST OF EUROPE: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 27 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SNAPSHOT
TABLE 102 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 103 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 104 ASIA PACIFIC: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 105 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 106 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 107 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 108 ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.1 JAPAN
11.4.1.1 Growing geriatric population to drive market
TABLE 109 JAPAN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 110 JAPAN: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.4.2 CHINA
11.4.2.1 Favorable government regulations and heavy burden of infectious diseases to drive market growth
TABLE 111 INCIDENCE OF INFECTIOUS DISEASES IN CHINA, 2020
TABLE 112 CHINA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 113 CHINA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Growing initiatives for clinical diagnosis by government and major players to drive market growth
TABLE 114 INDIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 115 INDIA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.4.4 AUSTRALIA
11.4.4.1 Increasing government funding for research activities to drive market growth
TABLE 116 AUSTRALIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 117 AUSTRALIA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.4.5 SOUTH KOREA
11.4.5.1 Requirement of rapid AMR detection to drive growth
TABLE 118 SOUTH KOREA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 119 SOUTH KOREA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.4.6 REST OF ASIA PACIFIC
TABLE 120 REST OF ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 121 REST OF ASIA PACIFIC: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.5 LATIN AMERICA
TABLE 122 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 123 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 124 LATIN AMERICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 125 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 126 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 127 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 128 LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.1 BRAZIL
11.5.1.1 Established presence of major AST product manufacturers to drive growth
TABLE 129 BRAZIL: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 130 BRAZIL: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.5.2 MEXICO
11.5.2.1 Growing economic development to drive market growth
TABLE 131 MEXICO: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 132 MEXICO: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.5.3 REST OF LATIN AMERICA
TABLE 133 REST OF LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 134 REST OF LATIN AMERICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 GROWING INCIDENCE OF INFECTIOUS DISEASES AND LARGE PATIENT POOL TO DRIVE MARKET GROWTH
TABLE 135 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 136 MIDDLE EAST & AFRICA: MANUAL ANTIMICROBIAL SUSCEPTIBILITY TESTING PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 137 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 138 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 139 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION)
TABLE 140 MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION)
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 STRATEGIES OF KEY PLAYERS/RIGHT TO WIN
TABLE 141 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 28 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
12.4 MARKET SHARE ANALYSIS (2021)
FIGURE 29 BIOM?RIEUX SA HELD LEADING POSITION IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET IN 2021
12.5 COMPANY EVALUATION MATRIX FOR 25 MAJOR PLAYERS (2021)
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 30 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2021
12.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2021)
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 31 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: COMPANY EVALUATION MATRIX FOR SMES/START-UPS, 2021
12.7 COMPETITIVE BENCHMARKING
TABLE 142 PRODUCT FOOTPRINT ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
TABLE 143 APPLICATION FOOTPRINT ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
TABLE 144 REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET
12.8 COMPETITIVE SCENARIO
12.8.1 PRODUCT LAUNCHES
TABLE 145 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: PRODUCT LAUNCHES, JANUARY 2020–JANUARY 2023
12.8.2 DEALS
TABLE 146 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DEALS, JANUARY 2020–JANUARY 2023
13 COMPANY PROFILES
(Business overview, Products offered, Recent Developments, MNM view)*
13.1 KEY PLAYERS
13.1.1 BIOM?RIEUX SA
TABLE 147 COMPANY OVERVIEW: BIOM?RIEUX SA
FIGURE 32 BIOM?RIEUX SA: COMPANY SNAPSHOT
13.1.2 BECTON, DICKINSON AND COMPANY
TABLE 148 COMPANY OVERVIEW: BECTON, DICKINSON AND COMPANY
FIGURE 33 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
13.1.3 THERMO FISHER SCIENTIFIC
TABLE 149 COMPANY OVERVIEW: THERMO FISHER SCIENTIFIC
FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
13.1.4 DANAHER CORPORATION
TABLE 150 COMPANY OVERVIEW: DANAHER CORPORATION
FIGURE 35 DANAHER CORPORATION: COMPANY SNAPSHOT
13.1.5 BIO-RAD LABORATORIES, INC.
TABLE 151 COMPANY OVERVIEW: BIO-RAD LABORATORIES, INC.
FIGURE 36 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
13.1.6 BRUKER
TABLE 152 COMPANY OVERVIEW: BRUKER
FIGURE 37 BRUKER: COMPANY SNAPSHOT
13.1.7 ROCHE DIAGNOSTICS
TABLE 153 COMPANY OVERVIEW: ROCHE DIAGNOSTICS
FIGURE 38 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
13.1.8 MERCK KGAA
TABLE 154 COMPANY OVERVIEW: MERCK KGAA
FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT
13.1.9 ACCELERATE DIAGNOSTICS, INC.
TABLE 155 COMPANY OVERVIEW: ACCELERATE DIAGNOSTICS, INC.
FIGURE 40 ACCELERATE DIAGNOSTICS, INC.: COMPANY SNAPSHOT
13.1.10 HIMEDIA LABORATORIES
TABLE 156 COMPANY OVERVIEW: HIMEDIA LABORATORIES
13.1.11 LIOFILCHEM S.R.L.
TABLE 157 COMPANY OVERVIEW: LIOFILCHEM S.R.L.
13.1.12 ALIFAX S.R.L.
TABLE 158 COMPANY OVERVIEW: ALIFAX S.R.L.
13.1.13 CREATIVE DIAGNOSTICS
TABLE 159 COMPANY OVERVIEW: CREATIVE DIAGNOSTICS
13.1.14 SYNBIOSIS
TABLE 160 COMPANY OVERVIEW: SYNBIOSIS
13.1.15 BIOANALYSE
TABLE 161 COMPANY OVERVIEW: BIOANALYSE
13.2 OTHER COMPANIES
13.2.1 ZHUHAI DL BIOTECH CO., LTD.
13.2.2 ELITECH GROUP
13.2.3 MAST GROUP LTD.
13.2.4 CONDALAB
13.2.5 GENEFLUIDICS, INC.
13.2.6 BIOTRON LTD.
13.2.7 INVIVOGEN
13.2.8 MP BIOMEDICALS
13.2.9 QUANTAMATRIX INC.
13.2.10 PML MICROBIOLOGICALS
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
